← Back
Data updated: Jun 28, 2026
RAYNER SURGICAL
Pharma Pharmaceuticals
RAYNER SURGICAL is a pharmaceutical company with 1 FDA-approved products.
2014
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules
RAYNER SURGICAL's Key Drugs
RAYNER SURGICAL's core commercial portfolio centers on OMIDRIA — its most strategically important drugs approved in the last 15 years.
RAYNER SURGICAL's Recent FDA Approvals
New NDA/BLA approvals for RAYNER SURGICAL over the last two years — novel drugs only, excluding generics and label supplements.
No recent approvals
RAYNER SURGICAL's Therapeutic Areas
Disease areas where RAYNER SURGICAL has approved drugs and an active pipeline. Weighted by commercial stage — approved drugs count most, then late-stage trials.
No indication data
RAYNER SURGICAL Pipeline Snapshot
Active clinical trials for RAYNER SURGICAL across all therapeutic areas, from ClinicalTrials.gov.
No active pipeline data available
Pro Expected Approvals & Milestones
Loading detailed analysis...
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OMIDRIA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Active trial monitoring
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Unlock Full Intelligence
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2014-05-30
- Latest
- 2017-12-08
- Applications
- 1